Table 4.

Individual patient outcomes

Patient	Age (years)	Histology	Response to MTR	EA consolidation	PFS (months)	OS (months)
1	60	DLBCL	CR	Yes	107+	107+
2	40	DLBCL	CR	Yes	123+	123+
3	54	Lymphoblastic lymphoma	PD	No	1.1	9.8
4	47	DLBCL	PR	No	12	14
5	71	DLBCL	PD	No	3	8
6	52	DLBCL	CR	No	48+	48+
7	43	DLBCL	CR	Yes	8.7	11
8	68	DLBCL	CR	No	104+	104+
9	45	Burkitt-like lymphoma	PD	No	2	22
10	62	DLBCL	PD	No	1	17
11	68	DLBCL	PD	No	8	8.5
12	79	DLBCL	PD	No	4	6.5
13	65	DLBCL	CR	Yes	95+	95+
14	59	Aggressive B-cell NHL	CR	Yes	24	66
15	61	DLBCL	CR	Yes	91+	91+
16	50	DLBCL	PD	No	1.2	6.4
17	81	Lymphoblastic lymphoma	CR	No	77	83
18	53	DLBCL	CR	Yes	90+	90+
19	79	DLBCL	PD	No	6	9
20	67	DLBCL	CR	No	51+	51+
21	84	DLBCL	PD	No	1	3
22	67	DLBCL	PD	No	3	6
23	49	DLBCL	PD	No	3	42.3
24	62	DLBCL	SD	Yes	80+	80+
25	63	DLBCL	CR	Yes	79+	79+
26	66	DLBCL	CR	Yes	54+	54+
27	52	DLBCL	CR	Yes	71+	71+
28	54	Burkitt-like lymphoma	CR	Yes	62+	62+
29	54	DLBCL	PR	Yes	6	54+
30	64	T-cell NHL	PD	No	3.8	5.7
31	54	DLBCL	CR	Yes	56+	56+

Abbreviations: DLBCL, diffuse large B-cell lymphoma; NHL, non-Hodgkin lymphoma; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; OS, overall survival